Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls

Date of Call: Mar 24, 2026

Business Commentary:

CardiAMP HF Trial Results:

• BioCardia presented late-breaking clinical trial results showing reductions in left ventricular volume in patients with ischemic heart failure, with p-values of 0.06 and 0.09 for end-systolic and end-diastolic volumes, respectively. In subgroups with elevated biomarkers, the p-values were 0.02 and 0.01.
• These results suggest that CardiAMP therapy may curb pathological ventricular remodeling and improve clinical outcomes, providing a basis for potential regulatory approvals.

Regulatory Pathways and Approvals:

• The company is preparing to submit a Q-Submission request to the FDA and engage with Japan's PMDA for potential approval of CardiAMP therapy.
• The focus is on extending existing labeling for the CardiAMP cell processing platform to include a therapeutic indication for ischemic heart failure.

Financial Performance and Cash Management:

• Total expenses increased by 3% year-over-year to $8.3 million, with a 13% rise in research and development costs.
• The company ended the year with $2.5 million in cash and expects consistent cash burn in 2026, emphasizing careful resource management.

Enrollment and Trial Progress:

• The CardiAMP HF II confirmatory trial has begun enrollment at four centers, with potential modifications if earlier approval is granted.
• Enrollment is being managed carefully, leveraging the strong data from the completed trials to support future regulatory discussions and trial design.

Sentiment Analysis:

Overall Tone: Positive

• Management emphasizes 'excellent' clinical outcomes, 'compelling signals of patient benefits,' and 'remarkably lovely data' from blinded echocardiography. They state the company is 'not alone' in seeking approvals, indicating strong market interest, and express confidence in a 'short timeline' for potential FDA approval via the De Novo pathway.

Q&A:

• Question from Landeron Egaña-Gorroño (H.C. Wainwright): Can you provide color on the P values for the end diastolic and systolic volumes in the complete population and how this data supports the narrative to PMDA?
  Response: P values in the full population are approaching significance (0.06 and 0.09), while the pre-specified subgroup with elevated biomarkers shows statistically significant results (p=0.02 and p=0.01). The data supports approval for this responsive subgroup, demonstrating the therapy stops pathological heart dilation.

• Question from Landeron Egaña-Gorroño (H.C. Wainwright): Do you have an estimate of the CardiAMP submission timeline to the FDA and how do you think about potential post-marketing study requirements?
  Response: A Q-Submission for approvability is imminent, with a potential 45-day standard sprint discussion. Post-marketing studies would likely be extensive, open-label, and focus on safety, echo, biomarker, and survival data, but would be relatively cost-effective.

• Question from Landeron Egaña-Gorroño (H.C. Wainwright): How does CardiAMP HF compete with other cell therapies for heart failure in regulatory discussions?
  Response: CardiAMP is seen as a leading therapy due to its minimally invasive delivery, cost-effectiveness, and robust efficacy data. It is additive to guideline therapy, and management is not concerned about competitive issues, viewing multiple approaches as beneficial for patients.

• Question from James Molloy (Alliance Global Partners): Can you talk about enrollment in the HF2 trial, challenges, and best practices?
  Response: Enrollment is starting slowly due to clinical team bandwidth focused on regulatory submission. Once FDA/PMDA discussions conclude, clarity will come on whether HF2 remains a randomized trial or becomes an open-label post-marketing study, which will impact enrollment strategy.

• Question from James Molloy (Alliance Global Partners): What should we be looking for in the upcoming six-month CMI data presentation at EuroPCR?
  Response: The data will provide more visibility into physician/patient experience. The CMI trial effectively doubles the market potential for CardiAMP, and there is interest in advancing it, especially if CardiAMP HF receives approval.

• Question from James Molloy (Alliance Global Partners): How would you characterize the environment for potential partnerships currently?
  Response: There is great interest, particularly in CardiAMP CMI and CardiALLO, driven by the potential early approval of CardiAMP HF. The new approval in Japan has created a fresh environment, and management expects increased partnership interest.

Contradiction Point 1

Enrollment Status and Strategy for the HF2 Trial

The status and near-term outlook for HF2 trial enrollment shifted from active, smooth progress to a paused, uncertain state.

James Molloy (Alliance Global Partners) - James Molloy (Alliance Global Partners)

2025Q4: Enrollment is starting slowly as the clinical team is primarily focused on regulatory submission efforts... Once conversations with FDA and PMDA conclude, it will be clear whether HF II remains a randomized trial or becomes an open-label post-marketing study, which will impact enrollment strategy. - Peter Altman(CEO)

Can you provide an update on enrollment progress, challenges, and best practices in centers for the HF2 trial? - James Molloy (Alliance Global Partners)

20251113-2025 Q3: Enrollment is proceeding "rather smoothly" and is "much, much easier" than the previous trial... Enrollment is expected to accelerate as the team focuses on it. - Peter Altman(CEO)

Contradiction Point 2

Characterization of the Competitive Environment for CardiAMP HF

The competitive landscape was described as positive and collaborative, then as requiring direct head-to-head trials.

James Molloy (Alliance Global Partners) - James Molloy (Alliance Global Partners)

2025Q4: The competitive landscape is positive for patients, with multiple companies pursuing options, and head-to-head trials may eventually occur. - Peter Altman(CEO)

How do you view the current environment for potential partnerships? - Kumaraguru Raja (Brookline Capital Markets)

20251113-2025 Q3: Interest in CardiAMP CMI and CardiALLO is expected to be driven by the progress of CardiAMP HF toward potential early approval in the U.S. or Japan. Business development discussions are ongoing. - Peter Altman(CEO)

Contradiction Point 3

Timeline and Process for FDA Submission and Approval

Contradiction on the expected timeline for regulatory submission and potential approval pathway.

Landeron Egaña-Gorroño (H.C. Wainwright) - Landeron Egaña-Gorroño (H.C. Wainwright)

2025Q4: An imminent Q-Submission request for approvability to the FDA’s CBER is planned. The timeline for a standard sprint discussion is estimated at ~45 days. Approval could potentially follow the De Novo pathway (if safety is not a concern), leading to a shorter and more straightforward process... - Peter Altman(CEO)

What is your estimated timeline for the CardiAMP FDA submission if everything goes according to plan, and how are you planning to address potential post-marketing study requirements? - James Francis Molloy (Alliance Global Partners)

2025Q2: If PMDA accepts the positioning, the approval process could take up to a year, similar to the FDA pathway. - Peter A. Altman(CEO)

Contradiction Point 4

Status and Strategy for the CardiAMP Heart Failure II (HF II) Trial

Contradiction on the trial's enrollment status and its relationship to regulatory submission.

James Molloy (Alliance Global Partners) - James Molloy (Alliance Global Partners)

2025Q4: Enrollment is starting slowly as the clinical team is primarily focused on regulatory submission efforts for the phase III data. Once conversations with FDA and PMDA conclude, it will be clear whether HF II remains a randomized trial or becomes an open-label post-marketing study... - Peter Altman(CEO)

Can you provide an update on enrollment progress in the HF2 trial, including any challenges and centers following best practices? - Lander Egaña-Gorroño (H.C. Wainwright)

2025Q2: The **CardiAMP Heart Failure II trial (BCDA-01)** is actively enrolling patients and will provide final top-line data in Q4 2025. - Peter A. Altman(CEO)

Contradiction Point 5

Characterization of the Partnership Environment

Contradiction on whether partnership discussions are active or on hold.

James Molloy (Alliance Global Partners) - James Molloy (Alliance Global Partners)

2025Q4: The environment is dynamic. With the recent first cardiac cell therapy approval in Japan, there is great interest in cell therapies. Interest in CardiAMP CMI and CardiALLO is expected to be driven by the progress of CardiAMP HF toward potential early approval in the U.S. or Japan. Business development discussions are ongoing. - Peter Altman(CEO)

What is the current environment like for potential partnerships? - James Francis Molloy (Alliance Global Partners)

2025Q2: Partnerships are not on hold. Active discussions are ongoing for the **Helix**, **Morph DNA**, and **CardiALLO** platforms. - Peter A. Altman(CEO)